Search This Blog

Monday, June 29, 2026

Evommune ends EVO756 chronic spontaneous urticaria program after Phase 2b trial fails

 

Evommune ends EVO756 chronic spontaneous urticaria program after Phase 2b trial fails primary endpoint

  • Company disclosed the Phase 2b outcome and program discontinuation for EVO756 in a recent SEC filing.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)